• Phil Taylor
• 24 Dec, 2018

Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients. Results from a planned interim analysis of the phase III JAVELIN Ovarian 100 trial showed that Bavencio (avelumab) was unable to improve progression-free survival (PFS) compared to control groups when used as a maintenance therapy.
Read more...